Journal of pain management and therapeutic care最新文献

{"title":"Initial Experience with Bupivacaine-Meloxicam Extended Formulation (Zynrelef^®) For Open Urologic Surgery.","authors":"C J Staniorski, A Madhavaram, D Sharbaugh, A Watts, R V Vasan, V N Pena, A M Quinn, J M Myrga, Y Krampe, J G Yabes, J E Chelly, B J Davies, B L Jacobs","doi":"10.36266/JPMTC/122","DOIUrl":"https://doi.org/10.36266/JPMTC/122","url":null,"abstract":"<p><strong>Introduction: </strong>The opioid epidemic has led to efforts to improve peri-operative pain control by using multiple modalities. The goal of this study was to evaluate the efficacy and safety of bupivacaine meloxicam extended formulation (Zynrelef^®) in open urologic surgery.</p><p><strong>Materials and methods: </strong>Patients who received Zynrelef^® during open prostatectomy and nephrectomy were retrospectively reviewed from April 2022 through December 2022. Opioid consumption, patient reported pain, and complications were collected.</p><p><strong>Results: </strong>A total of 116 patients were included, 44 of whom received Zynrelef^® (38%). The groups were similar in terms of comorbidities and procedures. Fifty-nine patients (51%) underwent prostatectomy and fifty-seven underwent radical or partial nephrectomy (49%). Morphine milligram equivalents decreased over the first three post-operative days in both groups. The largest difference in opioid consumption between the Zynrelef^® group vs the control group occurred on post-operative day 2, with patients in the with Zynrelef^® group consuming fewer narcotics (median morphine milligram equivalents 8 vs. 15, standardized bias 0.38). Patient reported pain on post-operative day 1 was clinically similar in the Zynrelef^® group vs the control group (5 vs. 4 on 10-point scale) while post-operative calls to the office (34% vs. 19%) and emergency visits (11% vs. 1%) were increased in those receiving Zynrelef^®. Three wound infections occurred in the Zynrelef^® group (7%), all following prostatectomy with none occurring in the control group.</p><p><strong>Conclusions: </strong>Zynrelef^® administration following urologic procedures may decrease opioid requirements post-operatively. However, the rate of wound infections, emergency visits, and postoperative calls may be increased compared to standard methods of pain control.</p>","PeriodicalId":520537,"journal":{"name":"Journal of pain management and therapeutic care","volume":"3 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}